MedPath

Dextroamphetamine Sulfate

Dextroamphetamine Sulfate Tablets, USP CII Rx only

Approved
Approval ID

9acdf000-fefe-47c7-a44c-0f7a65c5c05c

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Oct 23, 2023

Manufacturers
FDA

Tris Pharma Inc

DUNS: 947472119

Products 2

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Dextroamphetamine Sulfate

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code27808-089
Application NumberANDA206095
Product Classification
M
Marketing Category
C73584
G
Generic Name
Dextroamphetamine Sulfate
Product Specifications
Route of AdministrationORAL
Effective DateOctober 23, 2023
FDA Product Classification

INGREDIENTS (8)

DEXTROAMPHETAMINE SULFATEActive
Quantity: 5 mg in 1 1
Code: JJ768O327N
Classification: ACTIB
CALCIUM PHOSPHATEInactive
Code: 97Z1WI3NDX
Classification: IACT
SUCROSEInactive
Code: C151H8M554
Classification: IACT
D&C YELLOW NO. 10Inactive
Code: 35SW5USQ3G
Classification: IACT
CELLULOSE, MICROCRYSTALLINEInactive
Code: OP1R32D61U
Classification: IACT
FD&C RED NO. 40Inactive
Code: WZB9127XOA
Classification: IACT
MAGNESIUM STEARATEInactive
Code: 70097M6I30
Classification: IACT
SODIUM STARCH GLYCOLATE TYPE A POTATOInactive
Code: 5856J3G2A2
Classification: IACT

Dextroamphetamine Sulfate

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code27808-090
Application NumberANDA206095
Product Classification
M
Marketing Category
C73584
G
Generic Name
Dextroamphetamine Sulfate
Product Specifications
Route of AdministrationORAL
Effective DateOctober 23, 2023
FDA Product Classification

INGREDIENTS (8)

DEXTROAMPHETAMINE SULFATEActive
Quantity: 10 mg in 1 1
Code: JJ768O327N
Classification: ACTIB
CALCIUM PHOSPHATEInactive
Code: 97Z1WI3NDX
Classification: IACT
SUCROSEInactive
Code: C151H8M554
Classification: IACT
FD&C YELLOW NO. 6Inactive
Code: H77VEI93A8
Classification: IACT
MAGNESIUM STEARATEInactive
Code: 70097M6I30
Classification: IACT
CELLULOSE, MICROCRYSTALLINEInactive
Code: OP1R32D61U
Classification: IACT
FD&C RED NO. 40Inactive
Code: WZB9127XOA
Classification: IACT
SODIUM STARCH GLYCOLATE TYPE A POTATOInactive
Code: 5856J3G2A2
Classification: IACT

Drug Labeling Information

DRUG ABUSE AND DEPENDENCE SECTION

LOINC: 42227-9Updated: 10/23/2023

DRUG ABUSE AND DEPENDENCE

Controlled Substance

Dextroamphetamine sulfate is a Schedule II controlled substance.

Abuse

Dextroamphetamine sulfate has a high potential for abuse and misuse which can lead to the development of a substance use disorder, including addiction (see WARNINGS).
Dextroamphetamine sulfate can be diverted for non-medical use into illicit channels or distribution.

Abuse is the intentional non-therapeutic use of a drug, even once, to achieve a desired psychological or physiological effect. Misuse is the intentional use, for therapeutic purposes, of a drug by an individual in a way other than prescribed by a health care provider or for whom it was not prescribed. Drug addiction is a cluster of behavioral, cognitive, and physiological phenomena that may include a strong desire to take the drug, difficulties in controlling drug use (e.g., continuing drug use despite harmful consequences, giving a higher priority to drug use than other activities and obligations), and possible tolerance or physical dependence.

Misuse and abuse of amphetamines may cause increased heart rate, respiratory rate, or blood pressure; sweating; dilated pupils; hyperactivity; restlessness; insomnia; decreased appetite; loss of coordination; tremors; flushed skin; vomiting; and/or abdominal pain. Anxiety, psychosis, hostility, aggression, and suicidal or homicidal ideation have also been observed with CNS stimulants abuse and/or misuse. Misuse and abuse of CNS stimulants, including dextroamphetamine sulfate, can result in overdose and death (see OVERDOSAGE), and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection.

Dependence

Physical Dependence
Dextroamphetamine sulfate may produce physical dependence. Physical dependence is a state that develops as a result of physiological adaptation in response to repeated drug use, manifested by withdrawal signs and symptoms after abrupt discontinuation or a significant dose reduction of a drug.

Withdrawal signs and symptoms after abrupt discontinuation or dose reduction following prolonged use of CNS stimulants including dextroamphetamine sulfate include dysphoric mood; depression; fatigue; vivid, unpleasant dreams; insomnia or hypersomnia; increased appetite; and psychomotor retardation or agitation.

Tolerance
Dextroamphetamine sulfate may produce tolerance. Tolerance is a physiological state characterized by a reduced response to a drug after repeated administration (i.e., a higher dose of a drug is required to produce the same effect that was once obtained at a lower dose).

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Dextroamphetamine Sulfate - FDA Drug Approval Details